Prophylactic treatment with monoclonal antibodies targeting the CGRP pathway for migraine prevention-Reference-Cited by-同舟云学术

Prophylactic treatment with monoclonal antibodies targeting the CGRP pathway for migraine prevention

Published:2023-07-05 Issue:7 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Oteri Vittorio¹,Douba Zain²³,Rayi Appaji⁴,Letteri Federica⁵,Moscote-Salazar Luis Rafael⁶,Pacheco-Barrios Kevin⁷⁸,Celani Maria Grazia⁹,Eusebi Paolo¹⁰,Ricci Stefano¹¹,Sacco Simona¹²¹³¹⁴,Cantisani Teresa Anna¹⁵

Affiliation:

1. University of Catania; Catania Italy

2. University of Aleppo; Aleppo Syrian Arab Republic

3. Department of Hematology; Syrian Arab Republic Ministry of Health; Aleppo Syrian Arab Republic

4. Neurology; Charleston Area Medical Center; Charleston West Virginia USA

5. San Jacopo Hospital; Pistoia Italy

6. University of Cartagena; Cartagena Colombia

7. Neuromodulation Center, Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School; Boston USA

8. Vicerrectorado de Investigación, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud; Universidad San Ignacio de Loyola; Lima Peru

9. Department of Neurophysiopathology; Azienda Ospedaliera di Perugia; Perugia Italy

10. Cochrane Neurological Sciences Field; Perugia Italy

11. UO Neurologia; USL Umbria 1; Città di Castello Italy

12. University of L’Aquila; L’Aquila Italy

13. Neurology and Stroke Unit; Avezzano-Sulmona Hospital; L’Aquila Italy

14. Migraine Centre; San Salvatore Hospital; L’Aquila Italy

15. Cochrane Neurological Sciences Field Director; Perugia Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Reference67 articles.

1. The American Headache Society position statement on integrating new migraine treatments into clinical practice;American Headache Society;Headache,2019

2. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1);Ashina;Cephalalgia,2020

3. Assessment of erenumab safety and efficacy in patients with migraine with and without aura: a secondary analysis of randomized clinical trials;Ashina;JAMA Neurology,2022

4. Migraine therapeutics differentially modulate the CGRP pathway;Bhakta;Cephalalgia,2021

5. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study;Bigal;Headache,2008